KR20220080133A - 골수퍼옥시다제 저해제의 전구약물 - Google Patents
골수퍼옥시다제 저해제의 전구약물 Download PDFInfo
- Publication number
- KR20220080133A KR20220080133A KR1020227015015A KR20227015015A KR20220080133A KR 20220080133 A KR20220080133 A KR 20220080133A KR 1020227015015 A KR1020227015015 A KR 1020227015015A KR 20227015015 A KR20227015015 A KR 20227015015A KR 20220080133 A KR20220080133 A KR 20220080133A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- substituted
- unsubstituted
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962913417P | 2019-10-10 | 2019-10-10 | |
| US62/913,417 | 2019-10-10 | ||
| PCT/US2020/054896 WO2021072140A1 (en) | 2019-10-10 | 2020-10-09 | Prodrugs of myeloperoxidase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220080133A true KR20220080133A (ko) | 2022-06-14 |
Family
ID=75438074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227015015A Withdrawn KR20220080133A (ko) | 2019-10-10 | 2020-10-09 | 골수퍼옥시다제 저해제의 전구약물 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240067651A1 (https=) |
| EP (1) | EP4041735A4 (https=) |
| JP (1) | JP2022552834A (https=) |
| KR (1) | KR20220080133A (https=) |
| CN (1) | CN114945573A (https=) |
| AU (1) | AU2020363903A1 (https=) |
| BR (1) | BR112022006381A2 (https=) |
| CA (1) | CA3157260A1 (https=) |
| IL (1) | IL291891A (https=) |
| MX (1) | MX2022004203A (https=) |
| WO (1) | WO2021072140A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021178734A1 (en) * | 2020-03-05 | 2021-09-10 | Biohaven Therapeutics Ltd. | Method of treating amyotrophic lateral sclerosis with myeloperoxidase inhibitor |
| CN115403584B (zh) * | 2021-05-26 | 2024-04-02 | 长春金赛药业有限责任公司 | 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5436790A (en) * | 1989-04-19 | 1990-11-16 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Sulfer-containing xanthine derivatives as adenosin antagonists |
| MY140748A (en) * | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| WO2007069924A1 (en) * | 2005-12-15 | 2007-06-21 | Industrial Research Limited | Deazapurine analogs of 4'-aza-l-nucleosides |
| NZ544187A (en) * | 2005-12-15 | 2008-07-31 | Ind Res Ltd | Deazapurine analogs of 1'-aza-l-nucleosides |
| US20090054468A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Use 938 |
| ES2691671T3 (es) * | 2010-06-24 | 2018-11-28 | Alkermes Pharma Ireland Limited | Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato |
| JP6667092B2 (ja) * | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ | ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体 |
| WO2016140879A1 (en) * | 2015-03-03 | 2016-09-09 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzole prodrugs and their use |
| AU2018304508B2 (en) * | 2017-07-17 | 2021-06-10 | Astrazeneca Ab | MPO inhibitors for use in medicine |
-
2020
- 2020-10-09 CA CA3157260A patent/CA3157260A1/en active Pending
- 2020-10-09 KR KR1020227015015A patent/KR20220080133A/ko not_active Withdrawn
- 2020-10-09 AU AU2020363903A patent/AU2020363903A1/en not_active Abandoned
- 2020-10-09 CN CN202080070666.8A patent/CN114945573A/zh active Pending
- 2020-10-09 MX MX2022004203A patent/MX2022004203A/es unknown
- 2020-10-09 JP JP2022521147A patent/JP2022552834A/ja active Pending
- 2020-10-09 EP EP20874337.7A patent/EP4041735A4/en not_active Withdrawn
- 2020-10-09 US US17/766,539 patent/US20240067651A1/en not_active Abandoned
- 2020-10-09 WO PCT/US2020/054896 patent/WO2021072140A1/en not_active Ceased
- 2020-10-09 IL IL291891A patent/IL291891A/en unknown
- 2020-10-09 BR BR112022006381A patent/BR112022006381A2/pt not_active IP Right Cessation
Non-Patent Citations (4)
| Title |
|---|
| 1. Artursson, P., Karlsson, J., "Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells", Biochem. Biophys. Res. Commun., 175: 880, (1991). |
| 2. Bohets, H., Annaert, P., Van Beijsterveldt, L., Anciaux, K., Verboven, P., Meuldermans, W., Lavrijsen, K., "Strategies for absorption screening in drug discovery and development", 1: 367, (2001). |
| 3. Artursson, P., Palm, K., Luthman, K., "Caco-2 monolayers in experimental and theoretical predictions of drug transport" Adv. Drug Del. Rev., 64: 280, (2012). |
| 4. Shah, P., Jogani, V., Bagchi, T., Misra, A., "Role of Caco-2 cell monolayers in prediction of intestinal drug absorption", Biotechnol. Progr., 22: 186, (2006). |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021072140A1 (en) | 2021-04-15 |
| IL291891A (en) | 2022-06-01 |
| AU2020363903A1 (en) | 2022-03-24 |
| BR112022006381A2 (pt) | 2022-06-28 |
| MX2022004203A (es) | 2022-07-04 |
| US20240067651A1 (en) | 2024-02-29 |
| CN114945573A (zh) | 2022-08-26 |
| JP2022552834A (ja) | 2022-12-20 |
| EP4041735A4 (en) | 2023-11-22 |
| CA3157260A1 (en) | 2021-04-15 |
| EP4041735A1 (en) | 2022-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2974287T3 (es) | Derivado de anillo fusionado que tiene actividad inhibidora de MGAT-2 | |
| US20240165095A1 (en) | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | |
| US9643986B2 (en) | Factor D inhibitors useful for treating inflammatory disorders | |
| US10442782B2 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2024517812A (ja) | 免疫グロブリン及びその他のタンパク質を分解する強力なａｓｇｐｒ結合性化合物 | |
| US20200345700A1 (en) | Lsd1 inhibitor and preparation method and application thereof | |
| US20210340176A1 (en) | Compounds | |
| TW201446768A (zh) | S1p及/或atx調節劑 | |
| US20070275961A1 (en) | Triazolo ' 1, 5-A ! Pyrimidines and Their Use in Medicine | |
| EP2518067A1 (fr) | Dérives de N-[(1H-pyrazol-1-YL)aryl]-1H-indole ou 1H- indazole-3-carboxamide et leurs applications en thérapeutique comme antagonistes de P2Y12. | |
| US20260078103A1 (en) | Isoquinolones as pi3k inhibitors | |
| KR20220080133A (ko) | 골수퍼옥시다제 저해제의 전구약물 | |
| US20220135589A1 (en) | Targeted ubiquitination degradation brd4 protein compound, preparation method therefor and application thereof | |
| WO2022272133A2 (en) | Protein stabilizing compounds containing usp7 ligands | |
| EP2523552B1 (en) | Pyrazolo[1,5-a]pyrimidines as mark inhibitors | |
| TW202128686A (zh) | 稠合雜芳基類衍生物、其製備方法及其在醫藥上的應用 | |
| US20230312601A1 (en) | Thiazolo[5,4-b]pyridine malt-1 inhibitors | |
| US20250051313A1 (en) | Phthalazine derivatives as pyruvate kinase modulators | |
| EP4522158A2 (en) | Pak1 degraders and methods of use thereof | |
| CN112218878A (zh) | Ntcp抑制剂 | |
| WO2023235719A2 (en) | Stereoselective allosteric inhibitors of sarm1 | |
| EP3702354B1 (en) | Compound having erk kinase inhibitory activity and use thereof | |
| US20210052587A1 (en) | 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy | |
| US20260116923A1 (en) | Cyclic peptide il-1beta trap for the treatment of atherosclerosis and inflammatory disorders | |
| CN113087724B (zh) | 异噻唑并嘧啶酮类化合物，包含其的药物组合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
St.27 status event code: N-1-6-B10-B11-nap-PC1202 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |